OMERS ADMINISTRATION Corp Sells 4,100 Shares of Charles River Laboratories International, Inc. $CRL

OMERS ADMINISTRATION Corp cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,429 shares of the medical research company’s stock after selling 4,100 shares during the quarter. OMERS ADMINISTRATION Corp owned 0.11% of Charles River Laboratories International worth $9,389,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Charles River Laboratories International by 59.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,097 shares of the medical research company’s stock worth $534,000 after acquiring an additional 1,152 shares during the period. Public Employees Retirement System of Ohio grew its holdings in shares of Charles River Laboratories International by 2.0% during the 1st quarter. Public Employees Retirement System of Ohio now owns 14,969 shares of the medical research company’s stock worth $2,582,000 after purchasing an additional 287 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Charles River Laboratories International by 198.0% during the first quarter. Bank of Nova Scotia now owns 19,844 shares of the medical research company’s stock valued at $3,423,000 after purchasing an additional 13,185 shares during the period. First Trust Advisors LP increased its position in shares of Charles River Laboratories International by 44.5% during the first quarter. First Trust Advisors LP now owns 8,736 shares of the medical research company’s stock valued at $1,507,000 after purchasing an additional 2,689 shares during the period. Finally, Madison Asset Management LLC raised its stake in shares of Charles River Laboratories International by 7.2% in the first quarter. Madison Asset Management LLC now owns 16,752 shares of the medical research company’s stock valued at $2,890,000 after purchasing an additional 1,130 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on CRL shares. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research note on Monday, July 20th. Evercore reaffirmed an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. Finally, Barclays lifted their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus price target of $220.75.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This represents a 70.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $226.38 on Monday. The stock’s fifty day simple moving average is $198.80 and its 200 day simple moving average is $187.36. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The firm has a market cap of $10.90 billion, a price-to-earnings ratio of -60.21, a P/E/G ratio of 2.52 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $238.85.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the prior year, the business posted $2.34 earnings per share. The business’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.